



## ICNAS/University of Coimbra granted with first EU marketing authorization for the distribution of cyclotron produced Gallium-68

*The Institute of Nuclear Sciences Applied to Health (ICNAS) from the University of Coimbra (UC) and IBA announce the granting of the first EU marketing authorization for the distribution of cyclotron-produced Gallium-68 using a liquid target for human use*

**Coimbra, Portugal, 28 September 2021** – ICNAS/UC, leading institution in molecular probe development and molecular imaging and IBA (Ion Beam Applications S.A., EURONEXT), the world's leading provider of solutions for the diagnosis and treatment of cancer, today announce that the Portuguese regulatory agency (INFARMED), has granted the first EU marketing authorization to distribute [<sup>68</sup>Ga]GaCl<sub>3</sub> with a new process for producing gallium-68 with an IBA cyclotron using a liquid target.

<sup>68</sup>Ga has played an outstanding role in clinical research worldwide, particularly in routine clinical studies for oncological applications with Positron Emission Tomography (PET), during the last 10 years. In particular, <sup>68</sup>Ga is very well suited as a diagnostic isotope for pairing with therapeutic radiometal isotopes (ex: <sup>177</sup>Lu and <sup>225</sup>Ac). The growth of <sup>68</sup>Ga in routine clinical applications is mainly due to the [<sup>68</sup>Ga]Ga-PSMA-11 for PET imaging of the prostate specific membrane antigen (PSMA). The imaging of PSMA expression with [<sup>68</sup>Ga]Ga-PSMA-11 and PET/CT has proven to be a highly specific and sensitive tool for patient management.

*“This optimized new production process is the result of the strong collaboration between IBA and ICNAS”* said **Bruno Scutnaire, Vice-President of IBA's RadioPharma Solutions Division**.

This FGD-like production process is easy to implement and allows cyclotron production centers to maximize the use of their equipment. The process consists of the irradiation of an enriched <sup>68</sup>Zn solution in a <sup>68</sup>Ga liquid target installed on a Cyclone® KIUBE. The target solution is then transferred to a Synthera® extension module which purifies the irradiated solution to obtain [<sup>68</sup>Ga]GaCl<sub>3</sub>, which is equivalent to [<sup>68</sup>Ga]GaCl<sub>3</sub> from the commercial <sup>68</sup>Ge/<sup>68</sup>Ga generators.

*“Currently, the availability and efficiency of <sup>68</sup>Ge/<sup>68</sup>Ga generators is not enough to meet global demand and they have limited elution capacity per day and decay over time, while the <sup>68</sup>Ga-cyclotron process allows stable, on-demand production throughout the whole year”* commented **Antero Abrunhosa, Director at ICNAS**. *“We can see a clear benefit to producing <sup>68</sup>Ga with a cyclotron using a liquid target; the production is consistent and allows a higher production volume. This new patented process provides a viable alternative for facilities with cyclotrons securing <sup>68</sup>Ga access locally and for distribution.”*

Ends

### **About ICNAS/University of Coimbra**

ICNAS is a leading institution in molecular probe development and molecular imaging (given strong cyclotron and radiopharmacy related facilities). These pillars unite within the leading medical imaging center in Portugal (with PET and MR facilities) and have technical and scientific relevance at a European scale. ICNAS has unique expertise and equipment for development of imaging markers and studies in multi-modal and multi-organ imaging (eye, brain, heart, liver, prostate).

ICNAS can run preclinical trials and Phase 0 microdosing studies, and imaging clinical trials in Humans. It also develops new imaging techniques in partnership with the industry and labels candidate drugs for scientific and industry studies.

### **About IBA Radiopharma Solutions**

Based on longstanding expertise, IBA RadioPharma Solutions supports hospitals and radiopharmaceutical distribution centers with their in-house radioisotopes production by providing them with global solutions, from project design to the operation of their facility. In addition to high-quality technology production equipment, IBA has developed in-depth experience in setting up GMP radiopharmaceuticals production centers. More information can be found at: [www.iba-radiopharmaSolutions.com](http://www.iba-radiopharmaSolutions.com)

### **About IBA**

IBA (Ion Beam Applications) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.

IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)

**For further information please contact:**

#### **IBA RadioPharma Solutions**

**Rebecca Lo bue**

Marketing director

Tel : +32 10 20 12 75

[info-cyclo@iba-group.com](mailto:info-cyclo@iba-group.com)